NCT01874340View on ClinicalTrials.gov

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis

PHASE2TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Multiple Sclerosis
Interventions
DRUG

Placebo

Placebo will be administered at predefined visits over the 6-month treatment phase.

DRUG

AIN457

AIN457 will be administered at predefined visits over the 6-month treatment phase.

Trial Locations (13)

8000

Novartis Investigative Site, Bruges

17176

Novartis Investigative Site, Stockholm

44800

Novartis Investigative Site, Saint-Herblain

48013

Novartis Investigative Site, Bilbao

55139

Novartis Investigative Site, Atakum / Samsun

127018

Novartis Investigative Site, Moscow

194044

Novartis Investigative Site, Saint Petersburg

586 33

Novartis Investigative Site, Jihlava

00133

Novartis Investigative Site, Roma

556-0016

Novartis Investigative Site, Osaka

93-121

Novartis Investigative Site, Lodz

60-355

Novartis Investigative Site, Poznan

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY